- Home
- GENC vs BMEA Comparison
GENC vs BMEA Comparison
Compare GENC & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- BMEA
- Stock Information
- Founded
- GENC 1894
- BMEA 2017
- Country
- GENC United States
- BMEA United States
- Employees
- GENC N/A
- BMEA N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- GENC Industrials
- BMEA Health Care
- Exchange
- GENC Nasdaq
- BMEA Nasdaq
- Market Cap
- GENC 263.5M
- BMEA 145.0M
- IPO Year
- GENC N/A
- BMEA 2021
- Fundamental
- Price
- GENC $17.10
- BMEA $3.69
- Analyst Decision
- GENC
- BMEA Buy
- Analyst Count
- GENC 0
- BMEA 13
- Target Price
- GENC N/A
- BMEA $37.25
- AVG Volume (30 Days)
- GENC 29.2K
- BMEA 1.1M
- Earning Date
- GENC 02-04-2025
- BMEA 10-29-2024
- Dividend Yield
- GENC N/A
- BMEA N/A
- EPS Growth
- GENC 35.02
- BMEA N/A
- EPS
- GENC 1.11
- BMEA N/A
- Revenue
- GENC $113,116,000.00
- BMEA N/A
- Revenue This Year
- GENC N/A
- BMEA N/A
- Revenue Next Year
- GENC N/A
- BMEA N/A
- P/E Ratio
- GENC $15.97
- BMEA N/A
- Revenue Growth
- GENC 5.44
- BMEA N/A
- 52 Week Low
- GENC $15.24
- BMEA $3.61
- 52 Week High
- GENC $24.88
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- GENC 27.79
- BMEA 23.76
- Support Level
- GENC $16.50
- BMEA $3.74
- Resistance Level
- GENC $18.18
- BMEA $4.30
- Average True Range (ATR)
- GENC 1.07
- BMEA 0.41
- MACD
- GENC -0.31
- BMEA 0.00
- Stochastic Oscillator
- GENC 11.74
- BMEA 1.88
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.